Jose Gary Nadala, MD
Child & Adolescent Psychiatry · Lincoln, NENPI 1396882916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $795 and has fallen 86.9% since, to $104 in 2025.
Across 155 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$521
- Otsuka America Pharmaceutical, Inc.$516
- Supernus Pharmaceuticals, Inc.$314
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$295
- Takeda Pharmaceuticals U.S.A., Inc.$264
- Sunovion Pharmaceuticals Inc.$196
- plus $784 from 14 others
What the payments were for
- Food & beverage$2,890100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 24 | $521 |
| Otsuka America Pharmaceutical, Inc. | 30 | $516 |
| Supernus Pharmaceuticals, Inc. | 10 | $314 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $295 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $264 |
| Sunovion Pharmaceuticals Inc. | 13 | $196 |
| Ironshore Pharmaceuticals Inc. | 8 | $169 |
| Neurocrine Biosciences, Inc. | 11 | $157 |
| Shire North American Group Inc | 6 | $83 |
| AbbVie(2 entities) | 4 | $72 |
| Adlon Therapeutics L.p. | 4 | $71 |
| Lundbeck LLC | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Biogen | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$238
How this compares
Too few child & adolescent psychiatry providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 31 | $243,466 |
| Invega SustennaPaliperidone Palmitate | 20 | $53,711 |
| RexultiBrexpiprazole | 25 | $40,125 |
| VraylarCariprazine Hcl | 25 | $39,332 |
| Clozapine OdtClozapine | 27 | $17,892 |
| Atomoxetine Hcl | 44 | $7,220 |
| Aripiprazole | 83 | $6,318 |
| Clozapine | 89 | $5,464 |
| BelsomraSuvorexant | 11 | $4,920 |
| Paliperidone ErPaliperidone | 36 | $3,164 |
| Quetiapine Fumarate | 132 | $2,944 |
| Risperidone | 149 | $2,732 |
| Fluvoxamine Maleate | 48 | $2,644 |
| Ziprasidone Hcl | 40 | $2,564 |
| Divalproex Sodium | 24 | $2,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $157 | $243,46631 claims |
| Johnson & JohnsonInvega Sustenna | $521 | $53,71120 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $516 | $40,12525 claims |
| AbbVieVraylar | $72 | $39,33225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few child & adolescent psychiatry providers in Nebraskaon file to place this against a meaningful peer group, so we don't.
Other child & adolescent psychiatry in Lincoln
- Brendan BrodersenLincoln$151
- Ashley MarcuccioLincoln$25
- Brian LubberstedtOmaha$25K
- Gina OlivetoOmaha$1K
- Ann TaylorOmaha$233
- Sheila Forsman BiermanOmaha$197
- Geetanjali SahuNorth Platte$111
- Jennifer InbarasuBoys Town$103
- Geoffrey AllisonBoys Town$80
- Laura NovoaBoys Town$41
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.